Six of the best abstracts presenting groundbreaking research in the field of hematology were selected by the Scientific Program Committee for the Presidential Symposium on Friday, June 15.
This not-to-be-missed session offered the following presentations:
First-in-human CLL1-CD33 compound CAR T cells as a two-pronged approach for the treatment of refractory acute myeloid leukemia (S149)
Fang Liu | Chengdu Military General Hospital, Chengdu, China
Compound CAR T cells targeting both CLL1 and CD33 simultaneously, demonstrate anti-tumor activity in preclinical studies as well as in a phase 1 clinical trial in patients with relapsed/refractory acute myeloid leukemia. The CLL1-CD33 cCAR T therapy was safe and well-tolerated.
Ribosomal lesions promote oncogenic mutagenesis (S150)
Sergey Sulima | KU Leuven, Leuven, Belgium
Mutations in ribosomal proteins not only result in hypoproliferation of cells, especially affecting blood lineages, but paradoxically also infer an increased risk of developing leukemia. The authors now demonstrate that the RPL10 R98S mutation increases oxidative stress and promotes mutagenesis, allowing for oncogenic transformation.
Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study (S151)
Valentin Goede | University Hospital, Cologne, Germany, St Marien Hospital, Cologne, Germany
This study confirms superiority of obinutuzumab (G) plus chlorambucil (Clb) over rituximab plus Clb, with a clinically meaningful improvement in overall survival and an absolute treatment-free duration of approximately four and a half years. The results support the use of G-Clb in the first line for CLL patients with comorbidities.
Chronic red blood cell transfusions impair the innate immune response to infectious cues by shaping macrophages towards an anti-inflammatory functional phenotype (S152)
Francesca Vinchi | New York Blood Center, New York, United States
In mice, repeated red blood cell transfusions attenuate the inflammatory response of macrophages to infectious stimuli, thereby negatively impacting the innate immune response. These results provide an additional explanation for the increased risk of infections in chronically transfused patients.
MPN CALR mutants promote cell-surface localization of TpoR which is obligatory for oncogenesis: Novel therapeutic avenues and rescue of congenital thrombocytopenia TpoR mutants (S153)
Christian Pecquet | Ludwig Institut for Cancer Research Ltd, Brussels, Belgium
Mutant CALR, a driver of myeloproliferative neoplasms, is shown to bind to TpoR, leading to its increased thermal stability and translocation of the complex to the cell-surface, which is required for hematopoietic cell transformation. CALR mutants were able to rescue the cell-surface localization and signaling of the TpoR R102P mutant found in congenital amegakaryocytic thrombocytopenia.
RELEVANCE: Phase III efficacy and safety study of lenalidomide plus rituximab (R2) versus rituximab plus chemotherapy, followed by rituximab, in previously untreated follicular lymphoma (S154)
Frank Morschhauser | Centre Hospitalier Universitaire Régional de Lille, Unité GRITA, Lille, France
In previously untreated patients with grade 1-3a follicular lymphoma, a chemotherapy-free combination of lenalidomide and rituximab (R2) showed similar efficacy and a different toxicity profile compared to standard treatment with rituximab and chemotherapy.